Plain-English translation of NCT07304154 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 1 β Testing in a small group (usually 20β80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called , which uses your own immune cells to help fight autoimmune nerve diseases that haven't responded well to standard medications. The study will first test different doses of the medication to find the safest and most effective amount, then expand to more patients at that recommended dose. Researchers want to understand how well this treatment works and what side effects it might cause.
Some people with multiple sclerosis, myasthenia gravis, or chronic inflammatory demyelinating polyneuropathy continue to struggle even after trying multiple standard treatments. This medication represents a new approach that might help patients whose diseases have proven difficult to control.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
You will receive two chemotherapy medicines to prepare your immune system, followed by an infusion of the treatment made from your own immune cells. The study has two phases: in the first phase, different groups of patients receive increasing doses to find the right amount; in the second phase, more patients receive the recommended dose. You will need to visit the clinic multiple times for treatment, blood tests, and monitoring to check how you respond and watch for any side effects.
AI-generated summary from trial data Β· Aug 23, 2026 Β· Not medical advice
United States